Aussie-based biotech firm considers convertible bonds – interview
Mesoblast is looking at alternative funding options, including convertible bonds but it will only issue these when the company is at a later stage of product development, says chief executive Silviu Itescu.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts